J Breast Cancer.  2012 Jun;15(2):148-156. 10.4048/jbc.2012.15.2.148.

Breast Cancer as an Acquired Thrombophilic State

• Kyriazi V

• KMID: 2242184
• DOI: http://doi.org/10.4048/jbc.2012.15.2.148

Abstract

Cancer is an acquired thrombophilic condition manifested by increased incidence of venous and arterial thromboembolic complications. Despite progress that has been achieved in treatments over the recent years, thromboembolism remains a major complication in patients with breast cancer; it is accompanied by significant morbidity and mortality. Approximately, 1% of breast cancer patients develop venous thromboembolism within 2 years with the highest incidence occurring in the 6 months post diagnosis. Metastatic disease and their comorbidities are the strongest predictors of the development of thrombotic event. The diagnosis of venous thromboembolism is associated with a higher risk of death within 2 years of diagnosis. Thromboembolic events in cancer patients range from abnormal laboratory coagulation tests without specific symptoms to massive thomboembolism and disseminated intravascular coagulation. The underlying pathophysiology is complex and includes the prothrombotic properties of cancer cells, which can be enhanced by anticancer treatment modalities, such as surgery, hormonal agents, and chemotherapy. Primary thromboprophylaxis in cancer patients should be individualized according to risk. For secondary prevention, several clinical studies have shown that low molecular weight heparin has improved patients' compliance, cancer outcomes and overall survival. This review summarizes the available data on the pathogenesis and clinical approach of hemostatic changes in breast cancer.

Keyword

Blood coagulation; Breast neoplasms; Hemostasis; Thrombosis

MeSH Terms

Blood Coagulation
Breast
Breast Neoplasms
Comorbidity
Compliance
Disseminated Intravascular Coagulation
Hemostasis
Heparin, Low-Molecular-Weight
Humans
Incidence
Secondary Prevention
Thromboembolism
Thrombosis
Venous Thromboembolism
Heparin, Low-Molecular-Weight

Reference

1. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 2009. 29:316–320.

2. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007. 25:70–76.

3. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994. 343:886–889.

4. Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer. 2006. 106:923–930.

5. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006. 166:458–464.

6. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983. 62:14–31.

7. Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. J Clin Oncol. 2002. 20:4111–4114.

8. Prandoni P, Lensing AW, Büller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992. 327:1128–1133.

9. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005. 31:104–110.

10. Boccaccio C, Comoglio PM. Khorana AA, Francis CW, editors. Oncogenes, cancer, and hemostasis. Cancer-associated Thrombosis New Findings in Translational Science, Prevention, and Treatment. 2007. London: Informa Healthcare;10–23.

11. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011. 2011:394740.

12. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002. 94:116–128.

13. Fernadez PM, Patierno SR, Rickles FR. Lugassy G, Falanga A, Kakkar AK, Rickles FR, editors. Tumor angiogenesis and blood coagulation. Thrombosis and Cancer. 2004. London: Martin Dunitz.

14. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009. 7:1421–1423.

15. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010. 59:841–850.

16. Andtbacka RH, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006. 243:96–101.

17. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994. 12:1266–1271.

18. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer. 2003. 98:1578–1586.

19. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984. 54:1264–1268.

20. Wall JG, Weiss RB, Norton L, Perloff M, Rice MA, Korzun AH, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B study. Am J Med. 1989. 87:501–504.

21. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991. 9:286–294.

22. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988. 6:276–281.

23. Lee JJ, Yu JY, Lee JH, Zhang WY, Kim TJ, Myung CS, et al. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Arch Pharm Res. 2010. 33:387–394.

24. Napoleone E, Zurlo F, Latella MC, Amore C, Di Santo A, Iacoviello L, et al. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells. Eur J Cancer. 2009. 45:470–477.

25. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. The Scottish Cancer Trials Breast Group. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ. 1995. 311:977–980.

26. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997. 79:2024–2027.

27. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol. 2004. 15:1622–1626.

28. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002. 359:2131–2139.

29. Acedo Sánchez JD, Batlle JF, Feijoo JB. Catheter-related thrombosis: a critical review. Support Cancer Ther. 2007. 4:145–151.

30. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004. 9:207–216.

31. Schwarz RE, Coit DG, Groeger JS. Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol. 2000. 7:441–449.

32. Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004. 15:590–593.

33. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006. 24:1112–1118.

34. Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008. 100:663–669.

35. Caine GJ, Stonelake PS, Lip GY, Blann AD. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett. 2007. 248:131–136.

36. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer. 2008. 99:1000–1006.

37. Lee AY. Diagnosis and treatment of cancer-related thrombosis. Hematol Educ. 2010. 4:306–310.

38. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005. 23:2123–2129.

39. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009. 27:4919–4926.

40. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, et al. A randomized phase II trial of a new anticoagulant apixaban, in metastatic cancer. 2009 ASCO Annual Meeting. 2009. 27:Abstract #20514.

41. Hoppensteadt D, Jeske W, Walenga JM, Fareed J. AVE5026: A new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antothrombotic activity for management of cancer associated thrombosis. 2008 ASCO Annual Meeting. 2008. 26:Abstract #14653.

42. Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol. 2010. 3:3.

43. Kirwan CC, McDowell G, McCollum CN, Byrne GJ. Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome. Anticancer Res. 2011. 31:2383–2388.

44. Prestidge T, Lee S, Harper P, Young L, Ockelford P. Survival in patients with malignancy and venous thromboembolism by tumour subtype and thrombus location. Intern Med J. 2012. 42:71–74.

45. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005. 23:2130–2135.